NICE hears Bayer's Nexavar appeal
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, on Friday heard Bayer's appeal against the institute's guidance that rejected Nexavar (sorafenib) for advanced hepatocellular carcinoma for use on the NHS.
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.